METHOD FOR PREDICTION OF SURVIVAL IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA Russian patent published in 2019 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to laboratory diagnostics, and enables predicting the survival rate in the patients with clear cell renal cell carcinoma (ccRCC). That is ensured by obtaining samples from tumor and normal kidney tissues, isolating mRNA from them, performing reverse transcription of mRNA and polymerase chain reaction in real time (PCR-RT) with reverse transcription products using sets of primers specific to reverse transcription products of mRNA genes, for measuring the level of mRNA expression, based on which the prognosis of the survival of the ccRCC patients is made by comparing the expression level of the mRNA genes of the CA9, VWF, BHLHE41, EGLN3, BAP1 and PLIN2 groups in the tumor tissue samples with level of expression of the same genes in samples from normal tissue, related to levels of mRNA expression of endogenous control gene, selected from group: GAPDH and ACTB. If the tumor tissue mRNA expression level values of at least two and more genes from the CA9, VWF, BHLHE41, EGLN3 and PLIN2 group exceed the mRNA expression of the same genes in the normal tissue samples by at least 3.3; 2; 2; 3.5 and 1.5 times respectively and simultaneously the BAP1 gene expression level is at least 2.5 times less than the mRNA expression level of the gene in the normal tissue samples, the favorable prognosis of 3.5-year survival of the patients is stated in each of these cases from the moment of diagnosing.

EFFECT: invention provides a fast and reliable prognosis of the survival rate for the ccRCC patients by increasing the efficiency and effectiveness of the studies.

8 cl, 5 tbl, 5 ex